Compare TransMedics Group Inc (TMDX) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Tencent Music Entertainment Group - ADR — how do they compare? TransMedics Group Inc trades at $85.89 (market cap $3.06B), while Tencent Music Entertainment Group - ADR trades at $7.96 (market cap $13.50B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 4.4× TransMedics Group Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.98% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | TME | |
|---|---|---|
Market Cap | $3.06B | $13.50B |
Sector | Technology | Media |
52-Week High | $150.42 | $26.36 |
52-Week Low | $61.99 | $7.89 |
Enterprise Value | $3.46B | $11.44B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with a bearish technical signal from moving averages but oversold RSI levels. The company reported strong Q2 2026 earnings with a beat on EPS and revenue growth of 6% year-over-year, though recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
The outlook is balanced: TME's low P/E of 9.46 and net income margin of 26.28% offer value, but slowing growth and rising debt pose risks. Analysts have a consensus price target of $12.15, suggesting upside, but investors should weigh competitive threats from rivals like ByteDance's Soda Music against the company's fan economy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
